Recurrent Colorectal Carcinoma Clinical Trials
22 clinical trials for Recurrent Colorectal Carcinoma across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" — RECRUITING · NA
- Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer — RECRUITING · PHASE1
- Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform — RECRUITING
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) — ACTIVE_NOT_RECRUITING · PHASE2
- LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer — ACTIVE_NOT_RECRUITING · PHASE1
- Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer — ACTIVE_NOT_RECRUITING · PHASE1
- Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer — COMPLETED · PHASE1
- Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery — TERMINATED · PHASE2
- Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma — COMPLETED · PHASE1
- Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer — COMPLETED · PHASE1
- Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction — COMPLETED · PHASE1
- APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery — COMPLETED · PHASE1
- Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC) — WITHDRAWN · PHASE2
- Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer — COMPLETED · PHASE2
- Molecular Study and Precision Medicine for Colorectal Cancer — OTHER
- Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery — COMPLETED · PHASE1
- Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver — COMPLETED · PHASE2
- Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas — COMPLETED · PHASE1
- Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia — OTHER · PHASE2
- TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors — TERMINATED · PHASE1
- FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer — TERMINATED · PHASE2
- Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors — COMPLETED · PHASE1
Refine this search